Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB11 | O95342 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | SCN1A | P35498 | 1/20 | 0.32 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.32 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.31 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.31 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.31 |
| ▸ | HTR7 | P34969 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22994841 | 0.80 | KDM4E (0.38) | CYP1A2CYP2D6TLR8TLR7 | |
| SCHEMBL25021649 | 0.75 | PDE10A (0.30) | — | |
| SCHEMBL19637079 | 0.75 | HTT (0.32) | CYP1A2CYP2D6TLR8TLR7 | |
| SCHEMBL22994768 | 0.75 | KDM4E (0.32) | — | |
| SCHEMBL19637432 | 0.72 | KDM4E (0.36) | TDP1TLR8 | |
| SCHEMBL19637369 | 0.71 | HTT (0.35) | CYP1A2 | |
| SCHEMBL19636917 | 0.64 | HRH3 (0.42) | — | |
| SCHEMBL21912198 | 0.63 | CRHR1 (0.34) | CRHR1 | |
| SCHEMBL26670372 | 0.61 | HTR7 (0.44) | CYP1A2CYP2D6HTR7 | |
| SCHEMBL21912065 | 0.61 | KDM4E (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3458445-B1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2021-02-17 | — | — | EP | disclosed |
| WO-2020118066-A1 | COMBINATION THERAPIES | Mirati Therapeutics, Inc. (US) | 2020-06-11 | — | — | WO | disclosed |
| WO-2020055756-A1 | COMBINATION THERAPIES | Mirati Therapeutics, Inc. (US) | 2020-03-19 | — | — | WO | disclosed |
| WO-2020055755-A1 | COMBINATION THERAPIES | Mirati Therapeutics, Inc. (US) | 2020-03-19 | — | — | WO | disclosed |
| WO-2020055760-A1 | COMBINATION THERAPIES | Mirati Therapeutics, Inc. (US) | 2020-03-19 | — | — | WO | disclosed |
| WO-2017201161-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2017-11-23 | — | — | WO | disclosed |